Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 188

Sort by

Sort Order Select

Journal Articles

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Geoffrey L. Uy, MD, Tapan M. Kadia, MD, Wendy Stock, MD, Jonathan E Brammer, MD, Osnat Bohana-Kashtan, PhD, Abi Vainstein, Ella Sorani, PhD, Hemda Chen, PharmD, John F. DiPersio, MD PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2630.

https://doi.org/10.1182/blood-2019-127121

Published: 2019

Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3053.

https://doi.org/10.1182/blood-2019-121675

Published: 2019

Journal Articles

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Congli Zhang, Xin-xin Cao, Dong-zhu Li, Jun Feng, MD, Lu Zhang, MD, Yan Zhang, Ming-hui Duan, MD, Miao Chen, MD, Chen Yang, Wei Wang, Dao-Bin Zhou, Jian Li, MD

Blood (2019) 134 (Supplement_1): 2127.

https://doi.org/10.1182/blood-2019-125505

Published: 2019

Journal Articles

Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece

Maria Dimou, MD PhD, Vasileios Pardalis, MD PhD, Theodoros Iliakis, MD, Aikaterini Bitsani, MD, Ioannis Grafakos, MD, Sotiria Kalyva, PhD, Athanasios Markopoulos, PhD, Marie-Christine Kyrtsonis, MD PhD, Panayiotis Panayiotidis, MD

Blood (2019) 134 (Supplement_1): 3429.

https://doi.org/10.1182/blood-2019-122834

Published: 2019

Journal Articles

The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Blood (2018) 132 (Supplement 1): 535.

https://doi.org/10.1182/blood-2018-99-113274

Published: 2018

Journal Articles

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Blood (2018) 132 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2018-99-119861

Published: 2018

Journal Articles

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Blood (2018) 132 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2018-99-111929

Published: 2018

Journal Articles

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Ajai Chari, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Hareth Nahi, MD PhD, Jie Tang, Peter Hellemans, Brenda Tromp, MSc, Pamela L Clemens, PhD, Andrew Farnsworth, Jesus F San-Miguel, MD PhD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2018-99-113590

Published: 2018

Journal Articles

A Unique Case of Type 3 Von Willebrand Disease

Mamatha Mandava, MD, John Lazarchick, MD, Emily Curl, Shayla Bergmann, MD

Blood (2018) 132 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2018-99-112976

Published: 2018

Journal Articles

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2018-99-112179

Published: 2018

Journal Articles

Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation

Hillard M Lazarus, MD, Leland Metheny, MD, Tsila Zuckerman, MD, Carolina Escobar, MD, Joseph P. McGuirk, DO, Yael Rosen, MD, Jacob M. Rowe, MD

Blood (2018) 132 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2018-99-116239

Published: 2018

Journal Articles

Role of AML1-ETO Related Fusion Circular RNA in the Growth of Leukemia Cells

Ying Wang, MD, Yingxi Xu, PhD, Qian Liu, Haiyan Xing, MS, Zheng Tian, BS, Kejing Tang, BS, Qing Rao, MS, Min Wang, MD, Jianxiang Wang, MD

Blood (2018) 132 (Supplement 1): 5130.

https://doi.org/10.1182/blood-2018-99-112728

Published: 2018

Journal Articles

Safety and Efficacy of Romiplostim in over 200 Children with Immune Thrombocytopenia (ITP): Results of an Integrated Database of 5 Clinical Trials

Michael D. Tarantino, MD, Jenny M. Despotovic, DO, MS, John Roy, John Grainger, MD MRCP, FRPATH, Nichola Cooper, MRCP, Donald Beam, Ashok Raj, Alexey A. Maschan, MD, June Kim, PhD, Melissa Jeanne Eisen, MD

Blood (2018) 132 (Supplement 1): 2428.

https://doi.org/10.1182/blood-2018-99-109763

Published: 2018

Journal Articles

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Blood (2018) 131 (23): 2515–2527.

https://doi.org/10.1182/blood-2017-12-823757

Published: 2018

Includes: Supplemental data

Journal Articles

Nonacog Beta Pegol for Prophylactic Treatment of Children with Hemophilia B: Up to 3.5-Year Data from the Paradigm™5 Clinical Trial

Susan Kearney, MD, Elena Santagostino, Manuel Carcao, MD, Faraizah Abdul Karim, MD, Masashi Taki, MD PhD, Meng Yao Lu, MD, May-Lill Garly, MD PhD, Marek Zak, MD PhD

Blood (2017) 130 (Supplement 1): 1092.

https://doi.org/10.1182/blood.V130.Suppl_1.1092.1092

Published: 2017

Journal Articles

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael Tarantino, James B. Bussel, MD, Victor S. Blanchette, MD, Donald Beam, John Roy, Jenny M. Despotovic, DO, MS, Ashok Raj, Nancy Carpenter, Bhakti Mehta, Melissa Eisen

Blood (2017) 130 (Supplement 1): 14.

https://doi.org/10.1182/blood.V130.Suppl_1.14.14

Published: 2017

Journal Articles

Implantation of Patient-Derived Acute Leukemia Cells into the Hematopoietic Niche of Immunocompromised Mice Favors Faithful Recapitulation of the Disseminated Growth of Human Leukemia

Julia Schueler, DVM, PhD, Gabriele Greve, Dorothee Lenhard, Kerstin Klingner, Milena Pantic, PhD, Eva Oswald, PhD, Michael Lubbert, MD

Blood (2017) 130 (Supplement 1): 1427.

https://doi.org/10.1182/blood.V130.Suppl_1.1427.1427

Published: 2017

Journal Articles

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Ajai Chari, Hareth Nahi, Maria-Victoria Mateos, MD, Henk M. Lokhorst, Jonathan L. Kaufman, MD, Philippe Moreau, MDPhD, Albert Oriol, MD, Torben Plesner, MD, Lotfi Benboubker, MD, Peter Hellemans, Tara Masterson, Pamela L Clemens, Kevin Liu, Jesus F. San-Miguel, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 838.

https://doi.org/10.1182/blood.V130.Suppl_1.838.838

Published: 2017

Journal Articles

Targeting Burkitt's Lymphoma Using Novel, Discrete Carbon Nanotubes

Carolyne Falank, PhD, Aaron Tassett, BS, Sophie Harris, BA, Mariah Farrell, BS, Paul Everill, PhD, Michaela Reagan, PhD

Blood (2017) 130 (Supplement 1): 1476.

https://doi.org/10.1182/blood.V130.Suppl_1.1476.1476

Published: 2017

Journal Articles

Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease

Blood (2017) 130 (Supplement 1): 511.

https://doi.org/10.1182/blood.V130.Suppl_1.511.511

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece

The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

A Unique Case of Type 3 Von Willebrand Disease

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation

Role of AML1-ETO Related Fusion Circular RNA in the Growth of Leukemia Cells

Safety and Efficacy of Romiplostim in over 200 Children with Immune Thrombocytopenia (ITP): Results of an Integrated Database of 5 Clinical Trials

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Nonacog Beta Pegol for Prophylactic Treatment of Children with Hemophilia B: Up to 3.5-Year Data from the Paradigm™5 Clinical Trial

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Implantation of Patient-Derived Acute Leukemia Cells into the Hematopoietic Niche of Immunocompromised Mice Favors Faithful Recapitulation of the Disseminated Growth of Human Leukemia

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Targeting Burkitt's Lymphoma Using Novel, Discrete Carbon Nanotubes

Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only